CTOs on the Move

Joy Medical Group

www.joymedicalgroup.com

 
Joy Medical Group is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Kinerase

Kinerase is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

inVentiv Health

inVentiv Health, Inc. provides value-added services to the pharmaceutical, life sciences, and healthcare industries. The Company operates in four segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. The Company supports a range of clinical development, communications and commercialization activities that are critical to its customers' ability to complete the development of drug products and medical devices and commercialize them. In addition, the Company provides medical cost containment services to payors in its patient outcomes business. inVentiv provides services to over 350 client organizations, including global pharmaceutical companies, emerging and specialty biotechnology companies, and payors.

AnazaoHealth Corporation

AnazaoHealth Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Tampa, FL. To find more information about AnazaoHealth Corporation, please visit www.anazaohealth.com

County Of Ripley

County Of Ripley is a Doniphan, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celator Pharmaceuticals

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.